Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...
Hosted on MSN2d
Schrödinger’s stock pops as it enters collaboration pact with Novartis worth up to $2.5 billionSchrödinger Inc.’s stock soared 9% early Tuesday, after the company said it has entered a multi-year collaboration agreement ...
Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...
Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will ...
Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...
Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...
The majority of U.S. stock indices ended lower on Nov. 12, as rising U.S. treasury yields posed a headwind to the equities’ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback